Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $86
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $93 to $86.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $93 to $86.